Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at ...
Merck (NYSE:MRK) reported one year pivotal Phase 2b/3 data for remigromig in diabetic macular edema, showing non inferior ...
D’Amico concluded that remigromig is the first biologic with a novel mechanism of action that demonstrated a noninferior ...
Merck presents one-year results from the pivotal phase 2b/3 BRUNELLO study of remigromig in adults with diabetic macular edema at AAO 2026: Rahway, New Jersey Tuesday, October 13, ...
Merck (MRK) said its experimental eye drug remigromig improved vision in patients with a diabetes-related eye disease, meeting the main goal of a late-stage clinical trial. However, patients receiving ...
In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic ...
Voiant announces the publication of a peer-reviewed study in Nature's Eye evaluating a deep learning-based method for ...
Donald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular ...
Hosted on MSN
What To Know About Diabetic Macular Edema (DME)
Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when high blood sugar levels damage small blood vessels in the retina, the light-sensitive tissue at ...
Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results